Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
21.50    0.00 (0.00%)
Bid:
21.00
Ask:
22.00
Spread: 1.00 (4.762%)
Market Cap: £23.22m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Contract Wins

12 Jun 2024 07:00

RNS Number : 0440S
Checkit PLC
12 June 2024
 

12 June 2024

 

Checkit plc

("Checkit" or the "Group")

 

Contract Wins

 

Checkit (AIM: CKT), the automated monitoring platform for operational leaders, is pleased to announce a significant expansion with an existing US customer and a first customer for the recently launched AI module.

 

Contract Wins

 

The Group announces a significant expansion with Octaphama Plasma in the United States worth c.£718,000 over three years.

 

Octapharma will be expanding their use of the Checkit platform by integrating TTMUs (Tactical Temperature Monitoring Units) into their existing monitoring system, further protecting their operational data and mission-critical inventory. By leveraging the TTMUs offline data logging capabilities, Octapharma will have complete data redundancy across their entire network of plasma donation centres in the US. The investment highlights Octapharma's ongoing commitment to ensuring the safety and security of their plasma and operational data.

 

The Group is also pleased to announce a first signed contract for the recently launched Asset Intelligence product module, which applies advanced analytics and Machine Learning to IoT data which will help enhance customer sustainability, reduce costs, and improve revenue.

 

Commenting on the news Kit Kyte, Chief Executive Officer, said: "This latest win continues to validate our 'land and expand' strategy and demonstrates continued momentum in the US, a strategic priority for the business. Forward-thinking leaders like Octapharma understand why it's so critical to execute an operational data strategy, and we appreciate their trust and partnership. I am also thrilled that we have secured our first customer for the recently launched Asset Intelligence module, which marks the start of an exciting chapter in the evolution of our offering and our integrated end-to-end platform."

 

For further information, please visit www.checkit.net or contact:

 

Checkit plc

Kit Kyte (Chief Executive Officer)

Greg Price (Chief Financial and Operations Officer)

+44 (0) 1223 643313

Singer Capital Markets (Nominated Adviser & Broker)

Shaun Dobson / Peter Steel / James Fischer

+44 (0) 20 7496 3000

Tavistock (Financial PR)

Lulu Bridges / Katie Hopkins / Simon Hudson

+44 (0) 20 7920 3150

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTFLFITRLILLIS
Date   Source Headline
5th Dec 20117:00 amRNSDirector/PDMR Shareholding
30th Nov 20117:00 amRNSIssue of Equity
23rd Nov 201112:13 pmRNSHolding(s) in Company
22nd Nov 20111:14 pmRNSDirector/PDMR Shareholding
17th Nov 20117:00 amRNSTrading update
16th Nov 20111:24 pmRNSHolding(s) in Company
9th Nov 20117:00 amRNSHolding(s) in Company
4th Oct 20114:28 pmRNSDoc re. interim report and scrip dividend circular
20th Sep 20117:00 amRNSHolding(s) in Company
15th Sep 20117:00 amRNSHalf Yearly Report
24th Aug 201111:58 amRNSHolding(s) in Company
23rd Aug 20114:53 pmRNSDirector/PDMR Shareholding
23rd Aug 20114:46 pmRNSHolding(s) in Company
12th Aug 20117:00 amRNSIssue of Scrip Dividend Shares
29th Jul 20113:01 pmRNSDirector/PDMR Shareholding
29th Jul 20117:01 amRNSAppointment of Chief Financial Officer
29th Jul 20117:00 amRNSResult of AGM and Change of Name
28th Jul 20117:00 amRNSTrading Update
12th Jul 20115:02 pmRNSHolding(s) in Company
30th Jun 20114:58 pmRNSDoc re. Company's Scrip Dividend Scheme
28th Jun 20113:36 pmRNSAnnual Financial Report and Notice of AGM
16th Jun 20111:43 pmRNSHolding(s) in Company
19th May 201110:32 amRNSHolding(s) in Company
16th May 201112:03 pmRNSDirector/PDMR Shareholding
12th May 20117:00 amRNSPreliminary Results
12th Apr 20117:00 amRNSTechnology Update
10th Mar 20117:00 amRNSPre-Close Trading Update
1st Feb 20117:00 amRNSDirector/PDMR Shareholding
31st Jan 201110:24 amRNSDirector/PDMR Shareholding
20th Jan 20119:51 amRNSDirector/PDMR Shareholding and Total Voting Rights
13th Jan 20117:00 amRNSIssue of Equity
17th Dec 20107:00 amRNSTrading Statement
14th Dec 20108:42 amRNSHolding(s) in Company
2nd Dec 20107:00 amRNSHolding(s) in Company
15th Nov 20102:26 pmRNSDirectorate Change
9th Nov 20103:27 pmRNSHolding(s) in Company
5th Nov 20102:24 pmRNSHolding(s) in Company
5th Nov 20107:00 amRNSHolding(s) in Company
4th Nov 20107:00 amRNSDirector/PDMR Shareholding
1st Nov 20104:59 pmRNSHolding(s) in Company
27th Oct 201010:47 amRNSDirector/PDMR Shareholding
27th Oct 201010:47 amRNSDirector/PDMR Shareholding
5th Oct 20103:47 pmRNSDirector/PDMR Shareholding
27th Sep 20102:26 pmRNSDirector/PDMR Shareholding
24th Sep 20107:00 amRNSCompulsory Acquisition Procedure
23rd Sep 20104:32 pmRNSIssue of Equity
17th Sep 20107:00 amRNSIssue of Equity
16th Sep 20104:42 pmRNSHolding(s) in Company
16th Sep 20107:00 amRNSHalf Yearly Report
15th Sep 20101:54 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.